Overactive bladder

World Overactive Bladder Pipeline Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook - ResearchAndMarkets.com

Retrieved on: 
Monday, August 3, 2020
Health, Pharmaceutical, Food and Drug Administration, Health, RTT, Overactive bladder, Drug pipeline, Urinary bladder, Clinical trial

The "Overactive Bladder Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Overactive Bladder Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Good progress is anticipated during 2020 and 2021 with Overactive Bladder pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials.
  • The Overactive Bladder pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
  • The competitive intelligence report on Overactive Bladder presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Overactive Bladder pipeline.

FDA Approves First Treatment for a Form of Bladder Dysfunction in Pediatric Patients as Young as 2 Years of Age

Retrieved on: 
Tuesday, May 26, 2020
Urinary bladder disorders, Medical specialties, Medicine, Urology, Urinary system, RTT, Overactive bladder, Urinary bladder, Urinary incontinence, Urination

VESIcare (solifenacin succinate) tablets were initially approved in 2004 for the treatment of overactive bladder in adults 18 years and older.

Key Points: 
  • VESIcare (solifenacin succinate) tablets were initially approved in 2004 for the treatment of overactive bladder in adults 18 years and older.
  • NDO is a dysfunction of the bladder that results from disease or injury in the nervous system.
  • With NDO, there is overactivity of the bladder wall muscle, which normally relaxes to allow storage of urine.
  • The bladder wall muscle overactivity results in sporadic bladder muscle contraction, which increases pressure in the bladder and decreases the volume of urine the bladder can hold.

Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder

Retrieved on: 
Thursday, March 5, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Health, Urinary bladder disorders, Articles, Overactive bladder, RTT, OAB, Medication, Food and Drug Administration, Pharmaceutical industry, Beta3-adrenergic agonist, Solabegron, Urovant Sciences, Sumitomo Dainippon Pharma Co., Ltd.

Vibegron, if approved, would be the first new branded prescription drug for the treatment of OAB in nearly a decade and would offer these suffering patients another potential treatment option.

Key Points: 
  • Vibegron, if approved, would be the first new branded prescription drug for the treatment of OAB in nearly a decade and would offer these suffering patients another potential treatment option.
  • Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.
  • The Companys lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist that is being evaluated for overactive bladder (OAB).
  • The Company submitted a New Drug Application to the FDA seeking approval of vibegron for the treatment of patients with OAB in December 2019.

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology

Retrieved on: 
Monday, March 2, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Overactive bladder, RTT, Aromatic compounds, Chemical compounds, Monoclonal antibodies, Medical specialties, Immunosuppressants, Solabegron, Percutaneous tibial nerve stimulation, the Phase 3 Trial, Vibegron, Urovant Sciences

Urovant Sciences (Nasdaq: UROV) announced today the publication of the efficacy and safety results of vibegron in patients with overactive bladder (OAB) from the international Phase 3 EMPOWUR trial.

Key Points: 
  • Urovant Sciences (Nasdaq: UROV) announced today the publication of the efficacy and safety results of vibegron in patients with overactive bladder (OAB) from the international Phase 3 EMPOWUR trial.
  • The peer-reviewed publication is currently available online and the print article is scheduled to be published in the August issue of Journal of Urology.
  • The double-blind, placebo-controlled 12-week trial, in patients with OAB, studied vibegron 75 mg once-daily compared to placebo and included an active control.
  • Urovant Sciences reported positive data from the vibegron 12-week, Phase 3 pivotal EMPOWUR study and demonstrated favorable longer-term efficacy, safety, and tolerability in a 40-week extension study.

Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive Bladder

Retrieved on: 
Tuesday, February 4, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Biology, Medicine, Urinary bladder disorders, RTT, Overactive bladder, Urodynamic testing, OAB, Gene therapy, Detrusor muscle, Beta3-adrenergic agonist, the Phase 1 Trials, URO-902, Urovant Sciences

Urovant Sciences (Nasdaq: UROV) announced today the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder (OAB) from two double-blind, placebo-controlled randomized Phase 1 trials.

Key Points: 
  • Urovant Sciences (Nasdaq: UROV) announced today the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder (OAB) from two double-blind, placebo-controlled randomized Phase 1 trials.
  • URO-902 has the potential to be an important new treatment for patients with overactive bladder who have failed oral pharmacologic therapy.
  • Two doubleblind, placebocontrolled, multicenter Phase 1 trials were performed in female patients with OAB and urodynamically demonstrated detrusor overactivity (DO).
  • URO902, a gene therapy using a naked DNA plasmid vector, has the potential to be the first gene therapy for patients with OAB delivered directly into the bladder.

Axonics® Sacral Neuromodulation System Receives Reimbursement Approval in Germany

Retrieved on: 
Tuesday, February 4, 2020
Biotechnology, Surgery, Medical devices, Hospitals, Health, RTT, Medical specialties, Organs, Pelvis, Urinary bladder, Urinary system, Continence, Overactive bladder, Incontinence, Surgery, Medicine, Percutaneous tibial nerve stimulation

Extra funding was requested by 36 hospitals in Germany who wish to start using the Axonics r-SNM System in 2020.

Key Points: 
  • Extra funding was requested by 36 hospitals in Germany who wish to start using the Axonics r-SNM System in 2020.
  • These hospitals will now be allowed to benefit from specific reimbursement that yields a higher payment for the Axonics System as compared to the non-rechargeable SNM system currently marketed by the legacy provider.
  • Raymond W. Cohen, CEO of Axonics, commented, The large number of hospitals who have applied for NUB demonstrates the appetite of German physicians for the Axonics System.
  • The Axonics System obtained European CE Mark approval in June 2016 for the treatment of overactive bladder, urinary retention and fecal incontinence.

ANI Announces Launch of Tolterodine Extended-Release Capsules

Retrieved on: 
Friday, January 24, 2020
RTT, Muscarinic antagonists, Phenols, Tolterodine, Urinary incontinence, Overactive bladder, Urinary bladder, Medicine, Medical specialties, Organ systems, Treatments for overactive bladder

BAUDETTE, Minn., Jan. 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Tolterodine Extended-Release Capsules, 2 mg and 4 mg.

Key Points: 
  • BAUDETTE, Minn., Jan. 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Tolterodine Extended-Release Capsules, 2 mg and 4 mg.
  • The launch of Tolterodine ER capsules expands our commercial generic portfolio to 48 drugs."
  • Tolterodine Tartrate Extended-Release Capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
  • ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Axonics® Announces FDA Approval of Enhanced Neurostimulator Programmer

Retrieved on: 
Tuesday, January 21, 2020
Biotechnology, Hardware, Surgery, Health, FDA, Medical devices, Technology, Mobile, Wireless, Health, Prosthetics, Food and Drug Administration, United States Public Health Service, Overactive bladder, Urinary bladder, Implant, Continence, Incontinence, Medicine, Biotechnology

The new Programmer is used to program the Axonics external trial neurostimulator as well as the implantable neurostimulator in both the procedure and post-operative environments.

Key Points: 
  • The new Programmer is used to program the Axonics external trial neurostimulator as well as the implantable neurostimulator in both the procedure and post-operative environments.
  • FDA approval of the second-generation Programmer is part of an anticipated cadence of product enhancements in our robust product pipeline.
  • The long-lived, rechargeable, full-body MRI-compatible Axonics r-SNM System has obtained U.S. FDA approval, European CE Mark approval, Health Canada approval, and Australian Therapeutic Goods Administration approval for the treatment of overactive bladder, urinary retention and fecal incontinence.
  • Axonics launched commercially in the United States following FDA approval in late 2019.

Medtronic Receives CE Mark for InterStim™ Micro Neurostimulator and InterStim™ SureScan™ MRI Leads

Retrieved on: 
Monday, January 13, 2020
Branches of biology, Medicine, Neurotechnology, Organ systems, Neuromodulation, Neurophysiology, Neuropsychology, Pain, Sacral nerve stimulation, Medtronic, Overactive bladder, Magnetic resonance imaging

DUBLIN, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE Mark for its InterStim Micro neurostimulator and InterStim SureScan MRI leads clearing the technologies for commercial sale and clinical use in Europe.

Key Points: 
  • DUBLIN, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE Mark for its InterStim Micro neurostimulator and InterStim SureScan MRI leads clearing the technologies for commercial sale and clinical use in Europe.
  • InterStim Micro is a rechargeable device that delivers sacral neuromodulation therapy to treat overactive bladder (OAB), fecal incontinence (FI) and non-obstructive urinary retention.
  • The SureScan leads, which will be used in both the InterStim Micro system and in future implants of the existing recharge-free InterStim II, are designed to allow for full-body 1.5 and 3 Tesla MRI-conditional scans.
  • In addition, Medtronic is the only company in Europe to offer patients a choice between rechargeable and recharge-free systems that are both full-body MRI-conditional.

Global Overactive Bladder Treatment Market 2019-2024: Drivers Include New Technologies, Drug Development & Rising Number of Elderly People - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 9, 2020
Health, Pharmaceutical, RTT, Urinary bladder disorders, Overactive bladder, Branches of biology

Global Overactive Bladder Treatment Market: An Analysis

Key Points: 
  • Global Overactive Bladder Treatment Market: An Analysis
    6.1 Competitive Scenario of Global Overactive bladder treatment: By Therapy
    7.
  • Global Overactive Bladder Treatment Market: Regional Analysis
    7.1 Competitive Scenario of Global Overactive Bladder Treatment: By Region
    8.
  • North America Overactive Bladder Treatment Market: By Analysis
    8.1 North America Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
    8.4 North America Global Overactive Bladder Treatment Market: Country Analysis
    8.5 Market Opportunity Chart of North America Overactive Bladder treatment Market - By Country, By Value (Year-2024)
    8.7 United States Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
    8.8 United States Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
    8.9 Canada Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
    8.10 Canada Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
    8.11 Mexico Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
    8.12 Mexico Overactive Bladder Treatment Market Segmentation By Medication, By Therapy
    9.
  • ROW Overactive Bladder Treatment Market: Segmentation By Medication, By Therapy (2014-2024)
    11.1 ROW Overactive Bladder Treatment Market: Size and Forecast (2014-2024)
    13.4 Market Attractiveness Chart of Global Overactive Bladder Treatment Market - By Region, By Value, (Year-2024)